PLI.TO - ProMetic Life Sciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
1.60
-0.03 (-1.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.63
Open1.60
Bid1.60 x 0
Ask1.61 x 0
Day's Range1.58 - 1.61
52 Week Range1.12 - 3.24
Volume297,365
Avg. Volume1,007,585
Market Cap1.13B
Beta2.75
PE Ratio (TTM)-8.56
EPS (TTM)-0.19
Earnings DateMay 12, 2017 - May 15, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.16
  • Baystreet4 days ago

    Stocks in play: Prometic Life Sciences Inc.

    Announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application ...

  • CNW Group5 days ago

    Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)

    LAVAL, QC, Oct. 13, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX:PLI.TO - News) (OTCQX:PFSCF - News) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having  granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action date for April 14, 2018,  Ryplazim™ had previously been granted Fast Track, Orphan Drug and Rare Pediatric Disease designations by the U.S. FDA. "The acceptance of our BLA filing and setting of the PDUFA date by the FDA is a significant milestone for Prometic", said Mr. Pierre Laurin, President and Chief Executive Officer of Prometic.

  • PR Newswire5 days ago

    Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)

    LAVAL, QC, Oct. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having  granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action date for April 14, 2018,  Ryplazim™ had previously been granted Fast Track, Orphan Drug and Rare Pediatric Disease designations by the U.S. FDA. "The acceptance of our BLA filing and setting of the PDUFA date by the FDA is a significant milestone for Prometic", said Mr. Pierre Laurin, President and Chief Executive Officer of Prometic.

  • CNW Group9 days ago

    /R E P E A T -- Prometic Plasma Resources announces its participation to the International Plasma Awareness Week/

    WINNIPEG, Oct. 6, 2017 /CNW Telbec/ - Prometic Plasma Resources Inc., a subsidiary of Prometic Life Sciences Inc. (TSX:PLI.TO - News) (OTCQX:PFSCF - News) (Prometic), today announced its participation to the 2017 International Plasma Awareness Week (IPAW) to be held October 8 – 14. Events are held at plasma collection centers in Canada, the U.S. and Europe. This year, Prometic Plasma Resources is inviting a representative from the Canadian Immunodeficiencies Patient Organization (CIPO), http://www.cipo.ca, to visit the plasma center to meet our dedicated plasma donors.

  • Prometic Plasma Resources announces its participation to the International Plasma Awareness Week
    CNW Group11 days ago

    Prometic Plasma Resources announces its participation to the International Plasma Awareness Week

    WINNIPEG, Oct. 6, 2017 /CNW Telbec/ - Prometic Plasma Resources Inc., a subsidiary of Prometic Life Sciences Inc. (TSX:PLI.TO - News) (OTCQX:PFSCF - News) (Prometic), today announced its participation to the 2017 International Plasma Awareness Week (IPAW) to be held October 8 – 14. Events are held at plasma collection centers in Canada, the U.S. and Europe. This year, Prometic Plasma Resources is inviting a representative from the Canadian Immunodeficiencies Patient Organization (CIPO), http://www.cipo.ca, to visit the plasma center to meet our dedicated plasma donors.

  • Biotech Breakthroughs: 5 Stocks To Watch In 2017
    Baystreetlast month

    Biotech Breakthroughs: 5 Stocks To Watch In 2017

    This is a bull market, and some biotech stocks are the real raging bulls—especially when massive ...

  • Biotech Breakthrough Could Save Billions In Medical Expenses
    Baystreetlast month

    Biotech Breakthrough Could Save Billions In Medical Expenses

    Someone dies of a stroke every 4 minutes in the United States. Globally, 15 million people suffer ...

  • ProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation
    The Motley Fool2 months ago

    ProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation

    ProMetic Life Sciences Inc.'s (TSX:PLI) plasminogen drug Ryplazimä has been granted a "Rare Pediatric Disease" designation by the U.S. Food and Drug Administration, renewing investor interest in the Canadian bio-pharmaceutical company.

  • Baystreet3 months ago

    Stocks in play: Prometic Life Sciences Inc.

    Announced new long-term clinical data from its pivotal Phase 2/3 trial of Ryplazym™ (Plasminogen IV) ...